Etodolac News

Taro Receives Marketing Authorization in UK for Etopan XL Tablets 600 mg, Etodolac

Taro Pharmaceutical Industries Ltd. (“Taro”) reported today that Taro Pharmaceuticals (UK) Limited (“Taro UK”), its affiliate in the United Kingdom, has been granted a marketing authorization for Etopan XL Tablets 600 mg,...

FDA Safety Changes: Naprosyn/Anaprox and Other Prescription NSAIDs

The US Food and Drug Administration (FDA) has approved safety labeling revisions to advise of the potential risks for allergic reactions, gastrointestinal tract bleeding, and cardiovascular events associated with use of...

Comparing drugs for arthritis

Several years ago, when my arthritis began acting up, I started taking aspirin to relieve my pain and inflammation.

CHMP review of safety of non- selective NSAIDs, EMEA

What are the conclusions of the CHMP on cardiovascular safety of non-selective NSAIDs?

Taro Receives Approval for Etodolac extended Release Tablets ANDA 400 mg, 500 mg and 600 mg Strengths

Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS: TARO) reported today that its U.S. affiliate has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Etodolac...

Displaying results 1 to 5 out of 6

1

2

Next >

This site is intended solely for U.S. audiences; products described here may be subject to different medical and/or regulatory requirements in other countries. This site is for educational purposes only; information contained within should not be used to diagnose or treat a health problem or disease. Please consult a licensed health care provider regarding your medical condition.The products mentioned are trademarks of their respective owners.